Journal
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
Volume 54, Issue 7, Pages 498-501Publisher
DUSTRI-VERLAG DR KARL FEISTLE
DOI: 10.5414/CP202687
Keywords
fatty acid amide hydroxylase; endocannabinoids; phase I serious; adverse event; brain injury
Categories
Ask authors/readers for more resources
This short review focuses on the recent drug development of FAAH inhibitors, as recent serious adverse events have been reported in a phase I study with a compound of this class. The authors overview the potential interest in targeting FAAH inhibition, the current programs, and the available information on the recent dramatic events.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
